Bajaj Healthcare Limited (BAJAJHCARE) fundamentals
Bajaj Healthcare Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as BAJAJHCARE (ISIN INE411U01027). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Bajaj Healthcare Limited does
Bajaj Healthcare Limited is an India-based pharmaceutical company. The Company is engaged in activities of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), bulk drugs, branded and generic formulations. It is focused on development, manufacturing and supply of amino acids, nutritional supplements and API for pharmaceutical, nutraceuticals and food industries. It operates through three segments: APIs, Finished Dosage Formulations (FDFs), and Intermediates. Its APIs include Ascorbic Acid IP, Sodium Ascorbate, Ferrous Ascorbate, and others. Its Intermediary products include Calcium Phosphoryl Choline Chloride (CPCC) and Chlorhexidine (CH Base). It offers a range of FDFs forms, including tablets, caplets, capsules, and oral powders, all available in bulk quantities. The FDFs products include Cholecalciferol Sachet, Ticagrelor Tablet, Pancreatin Capsules, levofloxacin Tablets IP, Bisacodyl Tablet IP, and others.
Valuation and market data
| Last close | ₹333.10 |
|---|---|
| Market capitalisation | ₹1,076 crore |
| Enterprise value | ₹1,168 crore |
| P/E (TTM) | 0.00 |
| Price to book | 2.31 |
| Price to sales (TTM) | 1.69 |
| Book value per share | ₹144.31 |
| Dividend yield | 30.02% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Thu Nov 25 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹618 crore | ₹29 crore | ₹16 crore | 0.00 |
| Mar 2025 | ₹562 crore | ₹46 crore | ₹43 crore | 13.29 |
| Mar 2024 | ₹482 crore | ₹-17 crore | ₹-14 crore | -30.36 |
| Mar 2023 | ₹647 crore | ₹78 crore | ₹64 crore | 15.59 |
| Mar 2022 | ₹681 crore | ₹90 crore | ₹71 crore | 25.87 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 58.6% |
|---|---|
| Foreign institutions (FII) | 2.2% |
| Mutual funds | 1.7% |
| Other domestic institutions | 0.2% |
| Retail and others | 37.3% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.